

32692

Customer Number

Patent  
Case No.: 58327US004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: GRAHAM, PAUL D.

Application No.: 10/799960

Group Art Unit: 3739

Filed: March 12, 2004

Examiner: Henry M. Johnson III

Title: METHOD OF TATTOO REMOVAL

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR § 1.8(a)]

I hereby certify that this correspondence is being:

- ☒ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
- ☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 571-273-8300.

20 Jan. 2006

Date

Laci Burhop

Signed by: Laci Burhop

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

Copies of any cited foreign patents, foreign publications, non-patent literature documents, and any pending U.S. applications filed before June 30, 2003, are enclosed. Copies of any pending U.S. applications filed after June 30, 2003 that can be accessed on the USPTO's IFW system are not enclosed as per USPTO Waiver dated September 21, 2004. Copies of any U.S. patents and published U.S. patent applications are not enclosed.

01/24/2006 HVUONG1 00000024 133723 10799960

01 FC:1806 180.00 DA

This Information Disclosure Statement is being mailed after receipt of a first Office Action on the merits, but prior to the mailing of a Notice of Allowance under 37 CFR § 1.311. Please charge the fee for consideration of an Information Disclosure Statement set forth in 37 CFR § 1.17(p) to Deposit Account No. 13-3723, and if necessary, please charge any additional fees, or credit any overpayment to Deposit Account No. 13-3723. One copy of this sheet marked duplicate is also enclosed.

Respectfully submitted,

Date

1/19/2006

By:



Christopher D. Gram, Reg. No.: 43,643

Telephone No.: 651-733-1507

Office of Intellectual Property Counsel  
3M Innovative Properties Company  
Facsimile No.: 651-736-3833

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 1 of 1

## U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A1	US-			
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			

## Foreign Patent Documents

Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (If known)				
	B1						
	B2						
	B3						
	B4						
	B5						
	B6						
	B7						

## OTHER DOCUMENTS

Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation (Check if yes)
	C1	Gorden et al., "Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8", <u>The Journal of Immunology</u> , 2005, Vol. 174, pgs. 1259-1268.	
	C2	Sauder et al., "Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults", <u>Antimicrobial Agents and Chemotherapy</u> , December 2003, Vol. 47, No. 12, pgs. 3846-3852.	
	C3		

\*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.